Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.

Shida Y, Takahashi N, Sakamoto T, Ino H, Endo A, Hirama T.

J Clin Pharm Ther. 2014 Feb;39(1):97-101. doi: 10.1111/jcpt.12101.

PMID:
24117862
2.

Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.

Zhu Y, Wang Q, Frederick B, Bouman-Thio E, Marini JC, Keen M, Petty KJ, Davis HM, Zhou H.

Clin Drug Investig. 2013 Apr;33(4):291-301. doi: 10.1007/s40261-013-0072-2.

PMID:
23512638
3.

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus‚Ä©.

Sheikh SZ, Hammer AE, Fox NL, Groark J, Struemper H, Roth D, Gordon D.

Int J Clin Pharmacol Ther. 2016 Nov;54(11):914-922.

4.

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.

Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P.

J Drug Assess. 2013 Apr 12;2(1):40-8. doi: 10.3109/21556660.2013.792823.

5.
6.
7.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

White B, Leon F, White W, Robbie G.

Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

PMID:
19446146
8.

Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.

Zhuang Y, Xu Z, de Vries DE, Wang Q, Shishido A, Comisar C, Ford JA, Keen M, Achira M, Tsukamoto Y, Petty KJ, Davis HM, Zhou H.

Int J Clin Pharmacol Ther. 2013 Mar;51(3):187-99. doi: 10.5414/CP201785.

PMID:
23357841
9.

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.

Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group..

Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506.

11.
12.

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.

Struemper H, Murtaugh T, Gilbert J, Barton ME, Fire J, Groark J, Fox NL, Roth D, Gordon D.

Clin Pharmacol Drug Dev. 2016 May;5(3):208-15. doi: 10.1002/cpdd.219.

13.

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.

Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B.

Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816.

PMID:
24131736
14.

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA.

Br J Clin Pharmacol. 2010 Jun;69(6):645-55. doi: 10.1111/j.1365-2125.2010.03647.x.

15.

Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects.

Flouvat B, Leneveu A, Fitoussi S, Delhotal-Landes B, Gendron A.

Int J Clin Pharmacol Ther. 2004 Jan;42(1):50-7.

PMID:
14756388
16.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group..

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368.

17.

Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.

Wynne CJ, Ellis-Pegler RB, Waaka DS, Schwabe C, Lehle M, Heinzmann D, Mangat R, Li C, Dick AE, Cranshaw NA, Lum BL.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1079-87. doi: 10.1007/s00280-013-2273-z.

PMID:
24057039
18.

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Li H, Butler K, Yang L, Yang Z, Teng R.

Clin Drug Investig. 2012 Feb 1;32(2):87-97. doi: 10.2165/11595930-000000000-00000.

PMID:
22168538
19.

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J.

Clin Drug Investig. 2012 Jul 1;32(7):475-86. doi: 10.2165/11632780-000000000-00000.

PMID:
22650326
20.

Supplemental Content

Support Center